Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:15:33.690Z.
Calculation as of: 2026-10-06T16:15:33.690Z.
Quote observation: 2026-10-06T16:15:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6ac0f7718e38414e938d0d293bbdd3741326646c7ebae4135e2c8e12d98e3a9c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$984.36M
EV/EBITDA Ratio
11.49x
TTM Avg
10.94x
3Y Avg
46.55x
5Y Avg
35.86x
Market Cap
$992.02M
EV/EBITDA Ratio
4.89x
TTM Avg
6.06x
3Y Avg
6.06x
5Y Avg
6.06x
Market Cap
$992.10M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$998.12M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.01B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02B
EV/EBITDA Ratio
27.90x
TTM Avg
28.85x
3Y Avg
28.85x
5Y Avg
28.85x
Market Cap
$945.88M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aktis Oncology, Inc. (AKTS) | $982.85M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $984.36M | 11.49x | 10.94x | 46.55x | 35.86x |
| MeiraGTx Holdings plc (MGTX)vs › | $992.02M | 4.89x | 6.06x | 6.06x | 6.06x |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $992.10M | N/A | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $998.12M | N/A | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $1.01B | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $954.24M | N/A | N/A | N/A | N/A |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 27.90x | 28.85x | 28.85x | 28.85x |
| MoonLake Immunotherapeutics (MLTX)vs › | $945.88M | N/A | N/A | N/A | N/A |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $935.65M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
